TECH BUYER Jul 2021 - IDC Perspective - Doc # EUR148058821

Managing Cyber-Risks Across the Digital Transformation Journey: How Debiopharm is Undertaking a Security Transformation

By: Adriana AllocatoResearch Manager, Health Insights, IDC Europe, Nino GiguashviliSenior Research Analyst

Abstract

This IDC Perspective illustrates how Debiopharm (a Swiss biopharmaceutical company) embarked on a digital transformation journey in which cybersecurity has become a top priority. This report highlights the key elements of this journey, including the adoption of artificial intelligence solutions to protect the intellectual property of its business against cyberattacks.

"The life sciences landscape is experiencing dynamic changes that require a flexible and secure operating model. While pursuing their digital transformation journey, pharma companies must have cybersecurity strategies. This case study demonstrates the value of a cybersecurity solution offered by an expert and trusted vendor that has become essential for the pharma company," said Adriana Allocato, research manager, IDC Health Insights.


Coverage

Content


Get More

When you purchase this document, the purchase price can be applied to the cost of an annual subscription, giving you access to more research for your investment.



Related Links

Do you have questions about this document
or available subscriptions?

Contact Us